xenograft

If your drug fails in a xenograft, it will probably fail in the clinic.

But if your drug works in a xenograft, it will probably fail in the clinic, too.

Even with using xenografts instead of cell lines there's plenty of stuff that can go wrong.

As mattkrause notes below, that number is for mice with human tumor xenografts.

My project is to push that out to the 'xenograft' stage, which in my opinion is close to the limit, if not the limit.

Cloned mice receive tumor grown on human derived tissue so-called xenografts.

The reason for this is that the mouse model is called a xenograft model, you take a human cancer and implant it into the mouse.

That makes studies like the one cited here -- which involve the cancer-fighting activity of a mouse's own immune cells -- difficult to do with human xenografts.

That would immediately disqualify all xenograft models, and probably most native tumor models as well.

By a year after neonatal xenograft, the forebrain GPC populations of implanted mice were largely, and often entirely, of human origin.

We found that, in hGPC-xenografted mice, the human donor cells continue to expand throughout the forebrain, systematically replacing the host murine glia.

By 'nanorobot' they mean bacteria.>We show that when MC-1 cells bearing covalently bound drug-containing nanoliposomes were injected near the tumour in severe combined immunodeficient beige mice and magnetically guided, up to 55% of MC-1 cells penetrated into hypoxic regions of HCT116 colorectal xenografts.